Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cyril Planchais

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Cell Host & Microbe|July 11, 2023
Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controllerLuis M Molinos-Albert, Eduard Baquero, Mélanie Bouvin-Pley, et al.
International Journal of Biological Macromolecules|November 29, 2025
Optimized pipeline for generating highly potent neutralizing Affitins: Application to SARS-CoV-2 spike proteinThomas Maurice, Mélanie Laporte, Nicolas Barquilla, et al.
Journal of Virology|December 13, 2023
High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1William Bolland, Vincent Michel, Delphine Planas, et al.
The Journal of Infectious Diseases|March 11, 2021
Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2Ludivine Grzelak, Aurélie Velay, Yoann Madec, et al.
Nature Immunology|September 2, 2021
Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infectionNikaïa Smith, Pedro Goncalves, Bruno Charbit, et al.
The Journal of Experimental Medicine|June 25, 2020
Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllersVerena Hehle, Maxime Beretta, Maryline Bourgine, et al.
RMD Open|July 5, 2025
Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatismsMaxime Beretta, Emmanuel Martin, Olivier Fogel, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2022
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibodyJonathan L Torres, Gabriel Ozorowski, Emanuele Andreano, et al.
Biorxiv : the Preprint Server for Biology|November 23, 2022
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodiesDelphine Planas, Timothée Bruel, Isabelle Staropoli, et al.
Nature Communications|February 14, 2023
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodiesDelphine Planas, Timothée Bruel, Isabelle Staropoli, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Cell Host & Microbe|July 11, 2023
Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controllerLuis M Molinos-Albert, Eduard Baquero, Mélanie Bouvin-Pley, et al.
International Journal of Biological Macromolecules|November 29, 2025
Optimized pipeline for generating highly potent neutralizing Affitins: Application to SARS-CoV-2 spike proteinThomas Maurice, Mélanie Laporte, Nicolas Barquilla, et al.
Journal of Virology|December 13, 2023
High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1William Bolland, Vincent Michel, Delphine Planas, et al.
The Journal of Infectious Diseases|March 11, 2021
Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2Ludivine Grzelak, Aurélie Velay, Yoann Madec, et al.
Nature Immunology|September 2, 2021
Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infectionNikaïa Smith, Pedro Goncalves, Bruno Charbit, et al.
The Journal of Experimental Medicine|June 25, 2020
Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllersVerena Hehle, Maxime Beretta, Maryline Bourgine, et al.
RMD Open|July 5, 2025
Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatismsMaxime Beretta, Emmanuel Martin, Olivier Fogel, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2022
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibodyJonathan L Torres, Gabriel Ozorowski, Emanuele Andreano, et al.
Biorxiv : the Preprint Server for Biology|November 23, 2022
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodiesDelphine Planas, Timothée Bruel, Isabelle Staropoli, et al.
Nature Communications|February 14, 2023
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodiesDelphine Planas, Timothée Bruel, Isabelle Staropoli, et al.
Pageof 7